{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"4.000","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"1,056,213,761","primaryexch":"香港交易所","ric":"2552.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BF3S3D9","am":"21.02","iv":"","ew_strike":"","as":"3.870","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"3.850","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"1.130","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Robert Taylor Nelsen","underlying_ric":"2552.HK","hi52":"4.700","issuer_name":"華領醫藥 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"3.820","mkt_cap":"4.06","f_aum_hkd":null,"ew_sub_per_to":"","ls":"3.850","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.150","aum":"","issued_shares_class_B":null,"vo":"5.41","secondary_listing_flag":false,"listing_date":"2018年9月14日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"華領醫藥 - B","nm_s":"華領醫藥－Ｂ","sym":"2552","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"華領醫藥是一家主要從事用於治療2型糖尿病的口服新藥的開發及商業化的投資控股公司。該公司还從事华堂宁产品的商业化。該公司的主要產品管綫Dorzagliatin或HMS5552是一種葡萄糖激酶激活劑或GKA，旨在通過恢復2型糖尿病患者的血糖穩態平衡來控制糖尿病的漸進性退行性特性。该公司主要在国内市场开展业务。","op":"3.990","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港灣仔<br/>軒尼詩道200號<br/>恒生灣仔大廈<br/>506室","pc":"-3.75","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"4.000","isin":"KYG4644K1022","moneyness":""}},"qid":"1759074311909"}
